FDA: Stop SGLT2 Inhibitors Before Scheduled Surgery

FDA Approves Label Changes to SGLT2 Inhibitors Regarding Temporary Discontinuation of Medication Before Scheduled Surgery – U.S. Food & Drug Administration (free)

Commentary: FDA advises stopping SGLT2 inhibitor treatment prior to surgery – The Hospitalist (free)

“- Canagliflozin, dapagliflozin, and empagliflozin should each be discontinued at least three days before scheduled surgery.

– Ertugliflozin should be discontinued at least four days before scheduled surgery.

– Blood glucose levels should be carefully monitored after discontinuation of the SGLT2 inhibitor and appropriately managed before surgery.”